Results 51 to 60 of about 259,075 (330)

Case Report: Use of Subcutaneous Midazolam During an Episode of Catatonia

Frontiers in Psychiatry, 2021
Midazolam is a benzodiazepine (BZD) mainly used in anesthetic induction due to its pharmacokinetic features. Its place in the therapeutic management of catatonia remains to be determined. Here we present the case of a 65-year-old man who presented with a
Valentin Raymond, Etienne Véry, Adeline Jullien, Fréderic Eyvrard, Loic Anguill, Antoine Yrondi   +5 more
doaj   +1 more source

The impact of high frequency repetitive transcranial magnetic stimulation on fine motor function in medication resistant major depression [PDF]

, 2012
<b><i>Objectives:</i></b> Although high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) over the left dorsolateral prefrontal cortex (DLPFC) has been reported to improve mood symptoms in major depressive disorder (
Baeken, Chris, De Raedt, Rudi, Sabbe, Bernard GC, Schrijvers, Didier L   +3 more
core   +1 more source

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Psychopharmacology, 2017
Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment ...
R. Carhart-Harris, M. Bolstridge, M. Bolstridge, Camilla M. Day, Camilla M. Day, James Rucker, James Rucker, R. Watts, D. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, J. Rickard, Ben Forbes, A. Feilding, D. Taylor, H. Curran, D. Nutt   +18 more
semanticscholar   +1 more source

Ketamine in treatment-resistant depression

Industrial Psychiatry Journal
Sana Dhamija, Suprakash Chaudhury, Bhushan Chaudhari   +2 more
doaj   +3 more sources

Lamotrigine in the treatment of schizoaffective disorder [PDF]

, 1998
There is accumulating evidence for the efficacy of lamotrigine in the treatment of bipolar disorder, including bipolar depression, both as monotherapy and in combination with sodium valproate.
Erfurth, Andreas, Grunze, Heinz, Walden, Jörg   +2 more
core   +1 more source

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

American Journal of Psychiatry, 2019
OBJECTIVE About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective ...
V. Popova, E. Daly, M. Trivedi, K. Cooper, R. Lane, P. Lim, Christine Mazzucco, D. Hough, M. Thase, R. Shelton, P. Molero, E. Vieta, M. Bajbouj, H. Manji, W. Drevets, Jaskaran Singh   +15 more
semanticscholar   +1 more source

Predictors of prospective suicide attempts in a group at risk of personality disorder following self-poisoning

Frontiers in Psychiatry, 2023
BackgroundPatients with personality disorder (PD) are at risk for suicidal behavior and are frequently admitted for this reason to emergency departments.
Lionel Cailhol, Mariève Marcoux, Anjali Mathur, Antoine Yrondi, Philippe Birmes   +4 more
doaj   +1 more source

Surgical Treatment of Temporal Lobe Epilepsy Before and After Depression, Anxiety and Quality of Life Evaluation [PDF]

, 2011
Objectives: Depression and anxiety are the most common psychiatric disorders in patients with drug resistant temporal lobe epilepsy. This study evaluated depression, anxiety and quality of life in patients with temporal lobe epilepsy before and after ATL.
Atilla Erdem, Erhan Bilir, İrem Yıldırım Çapraz   +2 more
core   +1 more source

Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial

Nature Medicine
Disruption in reciprocal connectivity between the right anterior insula and the left dorsolateral prefrontal cortex is associated with depression and may be a target for neuromodulation.
R. Morriss, Paul M. Briley, L. Webster, M. Abdelghani, S. Barber, Peter Bates, Cassandra Brookes, Beth Hall, Luke Ingram, Micheal Kurkar, S. Lankappa, Peter F Liddle, R. H. McAllister-Williams, Alexander O'Neil-Kerr, S. Pszczólkowski, Ana Suazo Di Paola, Yvette Walters, D. Auer   +17 more
semanticscholar   +1 more source

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).

Journal of Clinical Psychiatry, 2020
OBJECTIVE To evaluate long-term safety and efficacy of esketamine nasal spray plus a new oral antidepressant (OAD) in patients with treatment-resistant depression (TRD).
E. Wajs, L. Aluisio, R. Holder, E. Daly, R. Lane, P. Lim, Joyce E George, R. Morrison, G. Sanacora, A. Young, S. Kasper, A. Sulaiman, Cheng-Ta Li, J. Paik, H. Manji, D. Hough, Jennifer Grunfeld, H. Jeon, S. Wilkinson, W. Drevets, Jaskaran Singh   +20 more
semanticscholar   +1 more source